NT529

NT529 is a preclinical-stage small molecule being developed by Neuroene Therapeutics for the treatment of medication-resistant seizures (refractory epilepsy). The compound is part of a pipeline focused on mitochondrial-targeted therapies designed to address the underlying metabolic and oxidative stress factors associated with neurological disorders. Neuroene's platform utilizes proprietary analogs of naturally occurring compounds, such as Vitamin K, to enhance mitochondrial function and provide neuroprotection. NT529 is specifically positioned for patients whose seizures are not adequately controlled by existing anti-epileptic medications, aiming to stabilize neuronal activity through improved mitochondrial health.